Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11664799 | 1.00 | DGKA (0.50) | DGKAMGLLMAPTDNM1LMNA | |
| SCHEMBL433535 | 0.98 | DGKA (0.47) | DGKAMGLLMAPTDNM1LMNA | |
| SCHEMBL28259218 | 0.96 | DGKA (0.46) | DGKAMGLLMAPTDNM1LMNA | |
| SCHEMBL9541849 | 0.93 | DGKA (0.62) | DGKAMGLLMAPTDNM1LMNA | |
| SCHEMBL2531968 | 0.92 | MGLL (0.46) | DGKAMGLLMAPTDNM1LMNA | |
| Propionic Acid SCHEMBL27714866 | 0.92 | DGKA (0.47) | DGKAMGLLMAPTDNM1LMNA | |
| SCHEMBL31402368 | 0.91 | DGKA (0.48) | DGKAMAPTDNM1LMNAKDM4E | |
| SCHEMBL4889959 | 0.90 | DGKA (0.61) | DGKAMAPTDNM1LMNAKDM4E | |
| SCHEMBL149453 | 0.90 | DGKA (0.61) | DGKAMAPTDNM1LMNAKDM4E | |
| SCHEMBL1278461 | 0.90 | DGKA (0.61) | DGKAMAPTDNM1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119924333-A | Use of ammonium ethyl phosphonate | 利民化学有限责任公司 | 2025-05-06 | — | — | CN | claimed |
| CN-118477023-A | Repairing agent and microemulsion with anti-wrinkle effect, composition, and preparation methods and applications thereof | 麦吉丽生物科技有限公司 | 2024-08-13 | — | — | CN | claimed |
| CN-113895064-B | PVC decorative film production process | 九江赛璐珞实业有限公司 | 2023-04-28 | — | — | CN | claimed |
| US-20230060820-A1 | OCTENIDINE SALT ANTIMICROBIAL MEDICAL ARTICLES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-03-02 | — | — | US | claimed |
| CN-113512196-B | Alcohol solution of alkyl silanol and preparation method | 中交上海三航科学研究院有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-114901069-A | Octenidine salt antimicrobial medical articles | 3M创新有限公司 | 2022-08-12 | — | — | CN | claimed |
| WO-1981002742-A1 | SIZING COMPOSITION FOR GLASS FIBERS | OWENS CORNING FIBERGLASS CORP (US) | 1981-10-01 | — | — | WO | claimed |
| WO-2026098542-A1 | PHARMACEUTICAL FORMULATIONS OF CURCUMIN AND/OR RESVERATROL COMPOUNDS | CALIWAY BIOPHARMACEUTICALS CO., LTD. (CN) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739274-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN REDUCING HYPERPIGMENTATION | Caliway Biopharmaceuticals Co. Ltd. (TW) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124160-A1 | PHARMACEUTICAL FORMULATIONS OF CURCUMIN AND/OR RESVERATROL COMPOUNDS | CALIWAY BIOPHARMACEUTICALS CO LTD (TW) | 2026-05-07 | — | — | US | disclosed |
| WO-2026087745-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732825-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-12605318-B2 | Synergistic preservative/personal care composition containing an alkylene glycol ester | ARCH UK BIOCIDES LTD (GB) | 2026-04-21 | — | — | US | disclosed |
| US-20070190124-A1 | Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs | NUVO RESEARCH INC. (CA) | 2007-08-16 | — | — | US | disclosed |
| US-20070189980-A1 | Compositions and methods for treating alopecia | ZARS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070189977-A1 | Spray-on formulations and methods for dermal delivery of drugs | ZARS, INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007070695-A2 | FLUX-ENABLING COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS | ZARS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070643-A2 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | ZARS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070694-A2 | SPRAY-ON FORMULATIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS | ZARS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070679-A2 | COMPOSITIONS AND METHODS FOR DERMALLY TREATING PAIN | ZARS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124160-A1 | PHARMACEUTICAL FORMULATIONS OF CURCUMIN AND/OR RESVERATROL COMPOUNDS | NLRP3, TRPV6, PYCARD | DGKA 4636/4885MGLL 2800/4885MAPT 2985/4885 |
| US-12605318-B2 | Synergistic preservative/personal care composition containing an alkylene glycol ester | DDC, ACMSD, SDC2 | DGKA 243/4885MGLL 158/4885MAPT 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.